Patents Assigned to Seneb Biosciences, Inc.
-
Publication number: 20160032342Abstract: The present invention relates to a novel endoglycoceramidase whose hydrolytic activity has been substantially reduced or eliminated, such that the enzyme is useful for synthesis of glycolipids from a monosaccharide or oligosaccharide and a ceramide. More specifically, the endoglycoceramidase is a mutant version of a naturally occurring endoglycoceramidase, preferably comprising a mutation within the active site or the nucleophilic site of the enzyme and more preferably comprising a substitution mutation of the Glu residue within the active site or the nucleophilic site. Also disclosed are a method for generating the mutant endoglycoceramidase and a method for enzymatically synthesizing glycolipids using this mutant enzyme.Type: ApplicationFiled: June 29, 2015Publication date: February 4, 2016Applicants: Seneb Biosciences, Inc., The University of British ColumbiaInventors: Karl F. JOHNSON, Shawn DEFREES, Stephen WITHERS, Mark VAUGHAN
-
Patent number: 9068208Abstract: The present invention relates to a novel endoglycoceramidase whose hydrolytic activity has been substantially reduced or eliminated, such that the enzyme is useful for synthesis of glycolipids from a monosaccharide or oligosaccharide and a ceramide. More specifically, the endoglycoceramidase is a mutant version of a naturally occurring endoglycoceramidase, preferably comprising a mutation within the active site or the nucleophilic site of the enzyme and more preferably comprising a substitution mutation of the Glu residue within the active site or the nucleophilic site. Also disclosed are a method for generating the mutant endoglycoceramidase and a method for enzymatically synthesizing glycolipids using this mutant enzyme.Type: GrantFiled: July 24, 2013Date of Patent: June 30, 2015Assignee: Seneb Biosciences, Inc.Inventors: Karl F. Johnson, Shawn Defrees, Stephen Withers, Mark Vaughan
-
Publication number: 20150005233Abstract: This invention provides compounds, compositions, and methods for treating hypogly.Type: ApplicationFiled: February 8, 2013Publication date: January 1, 2015Applicant: Seneb Biosciences, Inc.Inventor: Shawn DeFrees
-
Publication number: 20140147891Abstract: The present invention relates to a novel endoglycoceramidase whose hydrolytic activity has been substantially reduced or eliminated, such that the enzyme is useful for synthesis of glycolipids from a monosaccharide or oligosaccharide and a ceramide. More specifically, the endoglycoceramidase is a mutant version of a naturally occurring endoglycoceramidase, preferably comprising a mutation within the active site or the nucleophilic site of the enzyme and more preferably comprising a substitution mutation of the Glu residue within the active site or the nucleophilic site. Also disclosed are a method for generating the mutant endoglycoceramidase and a method for enzymatically synthesizing glycolipids using this mutant enzyme.Type: ApplicationFiled: July 24, 2013Publication date: May 29, 2014Applicants: The University of British Columbia University- Industry Liaison Office, Seneb BioSciences, Inc.Inventors: Karl F. Johnson, Shawn Defrees, Stephen Withers, Mark Vaughan
-
Publication number: 20120035120Abstract: This invention provides compounds, compositions, and methods for treating a disorder selected from cancer, hyperinsulinemia, hypoglycemia, hyperinsulinemia with hypoglycemia, atypical Parkinson's disease, Huntington's disease, multiple systems atrophy, GM3 synthase deficiency, GM2 synthase deficiency or tauopathy.Type: ApplicationFiled: March 25, 2010Publication date: February 9, 2012Applicant: SENEB BIOSCIENCES, INC.Inventor: Shawn DeFrees
-
Patent number: 7932236Abstract: Novel synthetic gangliosides and pharmaceutical compositions containing such synthetic gangliosides are described. Methods of making the novel synthetic ganglioside compounds and compositions as well as their use in the field of neuroprotection is also described.Type: GrantFiled: November 3, 2005Date of Patent: April 26, 2011Assignee: Seneb Biosciences, Inc.Inventors: Shawn DeFrees, Zhi-Guang Wang
-
Patent number: 7888331Abstract: Novel synthetic glycosphingolipids and pharmaceutical compositions containing such synthetic glycosphingolipids are described. Methods of making the novel synthetic glycosphingolipid compounds and compositions as well as their use in the field of neuroprotection and cancer treatment is also described.Type: GrantFiled: March 4, 2004Date of Patent: February 15, 2011Assignee: Seneb Biosciences, Inc.Inventors: Shawn A. Defrees, Karl Frank Johnson, Zhi-Guang Wang
-
Patent number: 7842677Abstract: Novel synthetic gangliosides and pharmaceutical compositions containing such synthetic gangliosides are described. Methods of making the novel synthetic ganglioside compounds and compositions as well as their use in the field of neuroprotection and cancer treatment is also described.Type: GrantFiled: August 29, 2002Date of Patent: November 30, 2010Assignee: Seneb Biosciences, Inc.Inventors: Shawn DeFrees, Zhi Guang Wang